SCHEMBL5130136

SCHEMBL5130136

CC(=O)CCCCC[C@H](NC(=O)c1ccccc1)C(=O)Nc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 17/20 0.59
▸ HDAC4 P56524 10/20 0.59
▸ HDAC3 O15379 8/20 0.59
▸ HDAC7 Q8WUI4 8/20 0.59
▸ HDAC2 Q92769 8/20 0.59
▸ HDAC10 Q969S8 8/20 0.59
▸ HDAC11 Q96DB2 8/20 0.59
▸ HDAC8 Q9BY41 8/20 0.59
▸ HDAC6 Q9UBN7 8/20 0.59
▸ HDAC9 Q9UKV0 8/20 0.59
▸ HDAC5 Q9UQL6 8/20 0.59
▸ MEF2D Q14814 2/20 0.57
▸ NCOR2 Q9Y618 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28316169 1.00 HDAC1 (0.59) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL14254988 0.90 HDAC1 (0.61) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL14254913 0.90 HDAC1 (0.61) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL14254912 0.88 HDAC1 (0.57) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL8337680 0.86 HDAC1 (0.71) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL14254985 0.86 HDAC1 (0.71) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL5127746 0.86 HDAC1 (0.59) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL28316507 0.86 HDAC1 (0.59) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL18395838 0.83 PADI1 (0.57) HDAC1HDAC4MEF2D
SCHEMBL14254991 0.82 HDAC1 (0.67) HDAC1HDAC4HDAC3HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221157-A1 Amide Derivatives as Inhibitors of Histone Deacetylase ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) 2008-09-11 — — US claimed
CN-110063951-A Improve the Compounds and methods for of impaired endogenous fibrinolysis using histone deacetylase mortifier 赛伦诺科学有限公司 2019-07-30 — — CN disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-20100048608-A1 Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases ALCON, INC. (CH) 2010-02-25 — — US disclosed
US-20080221157-A1 Amide Derivatives as Inhibitors of Histone Deacetylase ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) 2008-09-11 — — US disclosed
EP-1768955-A1 AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2007-04-04 — — EP disclosed
WO-2006005941-A1 AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) 2006-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC4 7/4885HDAC3 1/4885
US-20080221157-A1 Amide Derivatives as Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC4 HDAC1 1/4885HDAC4 3/4885HDAC3 7/4885
US-20100048608-A1 Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases HDAC1, HDAC3, HDAC5 HDAC1 1/4885HDAC4 4/4885HDAC3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback